{"entity":{"type":"insider","cik":"0001712882","url":"/insider/0001712882","json_url":"/insider/0001712882.json","name":"NEA 16 GP, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":21,"n_filings":17,"first":"2019-02-19","last":"2025-10-06","span_basis":"filed_date"},"name_variants":[{"name":"NEA 16 GP, LLC","source":"filing","n_filings":17,"first_seen":"2019-02-19","last_seen":"2025-10-06"}],"transactions":[{"id":4202055,"accession":"0001193125-25-232130","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-232130","line_url":"/filing/0001193125-25-232130#line-4","is_derivative":false,"issuer_cik":"0001671284","issuer_name":"NeueHealth, Inc.","issuer_ticker":"NEUE","issuer_name_source":null,"issuer_url":"/issuer/0001671284","owner_cik":null,"owner_name":"NEA 16 GP, LLC; NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":280.0,"shares_display":"280","price_per_share":6.75,"price_display":"6.75","price_state":"stated","total_value":1890.0,"total_display":"1,890.00","total_whole":"1,890","shares_owned_after":787979.0,"shares_owned_after_display":"787,979","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-02","filed_date":"2025-10-06","scope":"insider"},{"id":2652146,"accession":"0000950170-24-139630","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-139630","line_url":"/filing/0000950170-24-139630#line-1","is_derivative":false,"issuer_cik":"0001094038","issuer_name":"Marker Therapeutics, Inc.","issuer_ticker":"MRKR","issuer_name_source":null,"issuer_url":"/issuer/0001094038","owner_cik":null,"owner_name":"BASKETT FOREST; Behbahani Ali; Chang Carmen; Florence Anthony A. Jr.; Makhzoumi Mohamad; NEA 16 GP, LLC; NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.; SANDELL SCOTT D; Walker Paul Edward","owner_display_name":"BASKETT FOREST","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":554250.0,"shares_display":"554,250","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":1773600.0,"total_display":"1,773,600.00","total_whole":"1,773,600","shares_owned_after":1625678.0,"shares_owned_after_display":"1,625,678","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-23","filed_date":"2024-12-23","scope":"insider"},{"id":6516581,"accession":"0001209191-22-032327","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-032327","line_url":"/filing/0001209191-22-032327#line-2","is_derivative":false,"issuer_cik":"0001457612","issuer_name":"GENOCEA BIOSCIENCES, INC.","issuer_ticker":"GNCA","issuer_name_source":null,"issuer_url":"/issuer/0001457612","owner_cik":null,"owner_name":"NEA 16 GP, LLC; New Enterprise Associates 16, L.P.; NEA Partners 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4445093.0,"shares_display":"4,445,093","price_per_share":0.0816,"price_display":"0.08","price_state":"stated","total_value":362719.5888,"total_display":"362,719.59","total_whole":"362,720","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-25","filed_date":"2022-05-26","scope":"insider"},{"id":6516577,"accession":"0001209191-22-032327","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-032327","line_url":"/filing/0001209191-22-032327#line-1","is_derivative":false,"issuer_cik":"0001457612","issuer_name":"GENOCEA BIOSCIENCES, INC.","issuer_ticker":"GNCA","issuer_name_source":null,"issuer_url":"/issuer/0001457612","owner_cik":null,"owner_name":"NEA 16 GP, LLC; New Enterprise Associates 16, L.P.; NEA Partners 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5931843.0,"shares_display":"5,931,843","price_per_share":0.0654,"price_display":"0.07","price_state":"stated","total_value":387942.5322,"total_display":"387,942.53","total_whole":"387,943","shares_owned_after":4445093.0,"shares_owned_after_display":"4,445,093","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-24","filed_date":"2022-05-26","scope":"insider"},{"id":6250783,"accession":"0001209191-22-024301","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-024301","line_url":"/filing/0001209191-22-024301#line-1","is_derivative":false,"issuer_cik":"0001563880","issuer_name":"Trevi Therapeutics, Inc.","issuer_ticker":"TRVI","issuer_name_source":null,"issuer_url":"/issuer/0001563880","owner_cik":null,"owner_name":"NEA 16 GP, LLC; NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2631578.0,"shares_display":"2,631,578","price_per_share":1.9,"price_display":"1.90","price_state":"stated","total_value":4999998.2,"total_display":"4,999,998.20","total_whole":"4,999,998","shares_owned_after":10421428.0,"shares_owned_after_display":"10,421,428","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-11","filed_date":"2022-04-13","scope":"insider"},{"id":4958909,"accession":"0001209191-21-071265","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-071265","line_url":"/filing/0001209191-21-071265","is_derivative":false,"issuer_cik":"0001634379","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001634379","owner_cik":null,"owner_name":"NEA 16 GP, LLC; NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":459700.0,"shares_display":"459,700","price_per_share":0.9677028401131172,"price_display":"0.97","price_state":"stated","total_value":444852.9956,"total_display":"444,853.00","total_whole":"444,853","shares_owned_after":2734189.0,"shares_owned_after_display":"2,734,189","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-22","filed_date":"2021-12-27","scope":"insider","n_lines":2},{"id":4958894,"accession":"0001209191-21-071265","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-071265","line_url":"/filing/0001209191-21-071265#line-1","is_derivative":false,"issuer_cik":"0001634379","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001634379","owner_cik":null,"owner_name":"NEA 16 GP, LLC; NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37570.0,"shares_display":"37,570","price_per_share":1.321,"price_display":"1.32","price_state":"stated","total_value":49629.97,"total_display":"49,629.97","total_whole":"49,630","shares_owned_after":3022957.0,"shares_owned_after_display":"3,022,957","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-10","filed_date":"2021-12-27","scope":"insider"},{"id":4540305,"accession":"0001209191-21-061090","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-061090","line_url":"/filing/0001209191-21-061090#line-1","is_derivative":false,"issuer_cik":"0001563880","issuer_name":"Trevi Therapeutics, Inc.","issuer_ticker":"TRVI","issuer_name_source":null,"issuer_url":"/issuer/0001563880","owner_cik":null,"owner_name":"NEA 16 GP, LLC; New Enterprise Associates 16, L.P.; NEA Partners 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1851852.0,"shares_display":"1,851,852","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":7789850.0,"shares_owned_after_display":"7,789,850","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-18","filed_date":"2021-10-19","scope":"insider"},{"id":4619300,"accession":"0001209191-21-021809","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-021809","line_url":"/filing/0001209191-21-021809#line-1","is_derivative":false,"issuer_cik":"0001094038","issuer_name":"Marker Therapeutics, Inc.","issuer_ticker":"MRKR","issuer_name_source":null,"issuer_url":"/issuer/0001094038","owner_cik":null,"owner_name":"NEA 16 GP, LLC; NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5714285.0,"shares_display":"5,714,285","price_per_share":1.75,"price_display":"1.75","price_state":"stated","total_value":9999998.75,"total_display":"9,999,998.75","total_whole":"9,999,999","shares_owned_after":10714285.0,"shares_owned_after_display":"10,714,285","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-16","filed_date":"2021-03-18","scope":"insider"},{"id":3285531,"accession":"0001209191-20-061962","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-061962","line_url":"/filing/0001209191-20-061962#line-1","is_derivative":false,"issuer_cik":"0001505512","issuer_name":"Regulus Therapeutics Inc.","issuer_ticker":"RGLS","issuer_name_source":null,"issuer_url":"/issuer/0001505512","owner_cik":null,"owner_name":"New Enterprise Associates 16, L.P.; NEA 16 GP, LLC; NEA Partners 16, L.P.; Growth Equity Opportunities V, LLC","owner_display_name":"New Enterprise Associates 16, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4398602.0,"shares_display":"4,398,602","price_per_share":0.622,"price_display":"0.62","price_state":"stated","total_value":2735930.444,"total_display":"2,735,930.44","total_whole":"2,735,930","shares_owned_after":6451056.0,"shares_owned_after_display":"6,451,056","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-04","filed_date":"2020-12-07","scope":"insider"},{"id":2248432,"accession":"0001209191-20-051525","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-051525","line_url":"/filing/0001209191-20-051525#line-3","is_derivative":false,"issuer_cik":"0001634379","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001634379","owner_cik":null,"owner_name":"NEA Partners 16, L.P.; NEA 16 GP, LLC; New Enterprise Associates 16, L.P.","owner_display_name":"NEA Partners 16, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":769230.0,"shares_display":"769,230","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":3060527.0,"shares_owned_after_display":"3,060,527","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-18","filed_date":"2020-09-22","scope":"insider"},{"id":2967466,"accession":"0001209191-20-043862","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-043862","line_url":"/filing/0001209191-20-043862#line-1","is_derivative":false,"issuer_cik":"0001457612","issuer_name":"GENOCEA BIOSCIENCES, INC.","issuer_ticker":"GNCA","issuer_name_source":null,"issuer_url":"/issuer/0001457612","owner_cik":null,"owner_name":"NEA 16 GP, LLC; New Enterprise Associates 16, L.P.; NEA Partners 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3151260.0,"shares_display":"3,151,260","price_per_share":2.25,"price_display":"2.25","price_state":"stated","total_value":7090335.0,"total_display":"7,090,335.00","total_whole":"7,090,335","shares_owned_after":10376936.0,"shares_owned_after_display":"10,376,936","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-07-24","filed_date":"2020-07-28","scope":"insider"},{"id":3313712,"accession":"0001209191-20-039849","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-039849","line_url":"/filing/0001209191-20-039849#line-4","is_derivative":false,"issuer_cik":"0001694560","issuer_name":"Akouos, Inc.","issuer_ticker":"AKUS","issuer_name_source":null,"issuer_url":"/issuer/0001694560","owner_cik":null,"owner_name":"NEA Partners 16, L.P.; NEA 16 GP, LLC; New Enterprise Associates 16, L.P.","owner_display_name":"NEA Partners 16, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":588235.0,"shares_display":"588,235","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":9999995.0,"total_display":"9,999,995.00","total_whole":"9,999,995","shares_owned_after":4294207.0,"shares_owned_after_display":"4,294,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-30","filed_date":"2020-07-01","scope":"insider"},{"id":2139697,"accession":"0001209191-20-024314","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-024314","line_url":"/filing/0001209191-20-024314#line-1","is_derivative":false,"issuer_cik":"0001563880","issuer_name":"Trevi Therapeutics, Inc.","issuer_ticker":"TRVI","issuer_name_source":null,"issuer_url":"/issuer/0001563880","owner_cik":null,"owner_name":"NEA 16 GP, LLC; NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":564.0,"shares_display":"564","price_per_share":2.66,"price_display":"2.66","price_state":"stated","total_value":1500.24,"total_display":"1,500.24","total_whole":"1,500","shares_owned_after":5937998.0,"shares_owned_after_display":"5,937,998","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-04-03","filed_date":"2020-04-13","scope":"insider"},{"id":8166227,"accession":"0001209191-19-043052","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-043052","line_url":"/filing/0001209191-19-043052#line-2","is_derivative":false,"issuer_cik":"0001694560","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001694560","owner_cik":null,"owner_name":"New Enterprise Associates 16, L.P.; NEA Partners 16, L.P.; NEA 16 GP, LLC","owner_display_name":"New Enterprise Associates 16, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":450000.0,"shares_display":"450,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":6750000.0,"total_display":"6,750,000.00","total_whole":"6,750,000","shares_owned_after":4186243.0,"shares_owned_after_display":"4,186,243","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-22","filed_date":"2019-07-24","scope":"insider"},{"id":8567647,"accession":"0001209191-19-038946","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-038946","line_url":"/filing/0001209191-19-038946#line-1","is_derivative":false,"issuer_cik":"0001457612","issuer_name":"GENOCEA BIOSCIENCES, INC.","issuer_ticker":"GNCA","issuer_name_source":null,"issuer_url":"/issuer/0001457612","owner_cik":null,"owner_name":"NEA 16 GP, LLC; NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.","owner_display_name":"NEA 16 GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2857142.0,"shares_display":"2,857,142","price_per_share":3.5,"price_display":"3.50","price_state":"stated","total_value":9999997.0,"total_display":"9,999,997.00","total_whole":"9,999,997","shares_owned_after":7225676.0,"shares_owned_after_display":"7,225,676","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-24","filed_date":"2019-06-25","scope":"insider"},{"id":8514305,"accession":"0001209191-19-029388","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-029388","line_url":"/filing/0001209191-19-029388","is_derivative":false,"issuer_cik":"0001563880","issuer_name":"Trevi Therapeutics, Inc.","issuer_ticker":"TRVI","issuer_name_source":null,"issuer_url":"/issuer/0001563880","owner_cik":null,"owner_name":"New Enterprise Associates 16, L.P.; NEA 16 GP, LLC; NEA Partners 16, L.P.","owner_display_name":"New Enterprise Associates 16, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500000.0,"shares_display":"2,500,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":25000000.0,"total_display":"25,000,000.00","total_whole":"25,000,000","shares_owned_after":4438562.0,"shares_owned_after_display":"4,438,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-09","filed_date":"2019-05-13","scope":"insider","n_lines":2},{"id":7882750,"accession":"0001209191-19-028589","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-028589","line_url":"/filing/0001209191-19-028589#line-1","is_derivative":false,"issuer_cik":"0001505512","issuer_name":"Regulus Therapeutics Inc.","issuer_ticker":"RGLS","issuer_name_source":null,"issuer_url":"/issuer/0001505512","owner_cik":null,"owner_name":"NEA Partners 16, L.P.; New Enterprise Associates 16, L.P.; Growth Equity Opportunities V, LLC; NEA 16 GP, LLC","owner_display_name":"NEA Partners 16, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1136704.0,"shares_display":"1,136,704","price_per_share":1.08,"price_display":"1.08","price_state":"stated","total_value":1227640.32,"total_display":"1,227,640.32","total_whole":"1,227,640","shares_owned_after":2052454.0,"shares_owned_after_display":"2,052,454","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-07","filed_date":"2019-05-09","scope":"insider"},{"id":8451028,"accession":"0001209191-19-011145","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-011145","line_url":"/filing/0001209191-19-011145#line-1","is_derivative":false,"issuer_cik":"0001457612","issuer_name":"GENOCEA BIOSCIENCES, INC.","issuer_ticker":"GNCA","issuer_name_source":null,"issuer_url":"/issuer/0001457612","owner_cik":null,"owner_name":"NEA Partners 16, L.P.; NEA 16 GP, LLC; New Enterprise Associates 16, L.P.","owner_display_name":"NEA Partners 16, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9948269.0,"shares_display":"9,948,269","price_per_share":0.4713,"price_display":"0.47","price_state":"stated","total_value":4688619.1797,"total_display":"4,688,619.18","total_whole":"4,688,619","shares_owned_after":34948269.0,"shares_owned_after_display":"34,948,269","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-14","filed_date":"2019-02-19","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001671284","name":"NeueHealth, Inc.","url":"/issuer/0001671284","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2025-10-06","last_seen":"2025-10-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001094038","name":"Marker Therapeutics, Inc.","url":"/issuer/0001094038","role":"Ten percent owner","n_filings":2,"first_seen":"2021-03-18","last_seen":"2024-12-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001457612","name":"GENOCEA BIOSCIENCES, INC.","url":"/issuer/0001457612","role":"Ten percent owner","n_filings":4,"first_seen":"2019-02-19","last_seen":"2022-05-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001563880","name":"Trevi Therapeutics, Inc.","url":"/issuer/0001563880","role":"Ten percent owner","n_filings":4,"first_seen":"2019-05-13","last_seen":"2022-04-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001634379","name":"Metacrine, Inc.","url":"/issuer/0001634379","role":"Ten percent owner","n_filings":2,"first_seen":"2020-09-22","last_seen":"2021-12-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001505512","name":"Regulus Therapeutics Inc.","url":"/issuer/0001505512","role":"Ten percent owner","n_filings":2,"first_seen":"2019-05-09","last_seen":"2020-12-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001722271","name":"Akouos, Inc.","url":"/issuer/0001722271","role":"Ten percent owner","n_filings":1,"first_seen":"2020-07-01","last_seen":"2020-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001759425","name":"Mirum Pharmaceuticals, Inc.","url":"/issuer/0001759425","role":"Ten percent owner","n_filings":1,"first_seen":"2019-07-24","last_seen":"2019-07-24"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001712882","retrieved_at":"2026-08-22T09:13:51+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}